Serum Magnesium Levels in Desalination Tap Water and Outcomes in Acute Myocardial Infarction Patients

The Effect of Magnesium Serum Levels on Clinical Outcomes in Patients With Acute Myocardial Infarction by Considering Desalination Drinking Water Levels Patients Fed From.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02356393

Enrollment

150

Registered

2015-02-05

Start date

2015-05-31

Completion date

2023-12-01

Last updated

2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute-MI, Cardiovascular Disease, Congestive Heart Failure, Death, Myocardial Infarction

Keywords

Desalinated Sea Water, Magnesium, Drinking Water

Brief summary

Association between serum magnesium and clinical outcome in patients with acute MI (AMI) with 1 year follow-up in 300 patients in regions supplied by desalinated drinking water (DSW) (Sheba MC) and 150 patients in regions with non-desalinated drinking water (DW) (Nahariya MC).

Detailed description

Extensive seawater desalination in Israel may decrease magnesium in drinking water (DW), causing hypomagnesemia and adverse health effects. We study the association between consumption of desalinated drinking water (DSW) and serum magnesium in acute MI (AMI) patients, Subjects 35-75 years of age with the first AMI will be prospectively recruited during 1 year from 2 regions; the Departments of Cardiology at the Sheba Medical center (300 patients, predominantly served by DSW) and the Nahariya Medical Center (150 patients, served by non-DSW). Questionnaire will be developed to collect data on demographic variables (at home and work), water and beverages consumption habits (tap water, mineral water), dietary sources of Mg and Mg supplementations. Mg levels will be measured in DW from the patients' homes and in their serum on admission.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

35 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Patients with first AMI 2. Age 35-75

Exclusion criteria

1\. Patients \> age 75

Design outcomes

Primary

Measure	Time frame	Description
Number of Major Adverse Cardiovascular Events (MACE)	1 year	MACE including: acute infarct returns, revascularization, death within 30 days or one year, hospitalization for heart failure, hospitalization for angina pectoris and transient ischemic events.

Secondary

Measure	Time frame	Description
Age	1 year	Age at the first Acute Myocardial Infraction

Countries

Israel

Outcome results